Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.220 +0.180 (+3.57%)
Streaming Delayed Price Updated: 12:48 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 550,804
Open 5.070
Bid (Size) 5.210 (1,300)
Ask (Size) 5.220 (1,200)
Prev. Close 5.040
Today's Range 5.030 - 5.290
52wk Range 3.530 - 8.590
Shares Outstanding 93,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Thursday after market hours. Here’s what you need to know. Myriad Genet... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory

Performance

YTD
-15.0%
-15.0%
1 Month
-10.8%
-10.8%
3 Month
+11.5%
+11.5%
6 Month
-8.7%
-8.7%
1 Year
+27.3%
+27.3%

More News

Read More
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Via StockStory
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗
Via Chartmill
Topics Earnings
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Via StockStory
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
Via StockStory
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Via StockStory
Topics Bankruptcy
News headline image
3 High-Flying Stocks We’re Skeptical Of
Via StockStory
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
Via StockStory
Topics Energy
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
Via StockStory
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins
Via StockStory
News headline image
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%
Via StockStory
News headline image
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?
Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
What exchange does Myriad Genetics, Inc. - Common Stock trade on?
Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
What is the current price of Myriad Genetics, Inc. - Common Stock?
The current price of Myriad Genetics, Inc. - Common Stock is 5.220
When was Myriad Genetics, Inc. - Common Stock last traded?
The last trade of Myriad Genetics, Inc. - Common Stock was at 07/30/26 12:48 PM ET
What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
The market capitalization of Myriad Genetics, Inc. - Common Stock is 488.07M
How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
Myriad Genetics, Inc. - Common Stock has 488M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>